Silexion Therapeutics Corp (SLXN) stock
Close on Nov 13, 2026Market cap $1.19MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.19M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.40
- Dividend yield
- –
- Free cash flow yield
- -983.38%
Fundamentals
- Net income
- -$13.23M
- EPS, diluted
- $8.96
- Free cash flow
- -$11.74M
- Book value per share
- $16.05
- Diluted shares
- 0M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $2.66
- Open
- $2.55
- Day's range
- $1.82 – $2.62
- Volume
- 103,470
- Average volume (20 days)
- 307,709
- Beta (5 years)
- -0.36
- 52-week range
- $0.14 – $777.06
- RSI (14 days)
- 43.7
- Volatility (1 year)
- 10497.3%
- Relative volume
- 0.02×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SLXN | S&P 500 | Difference | SLXN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1025.0% | -3.0% | +1028.0 pts | ||
| 3 months | -82.1% | -2.8% | −79.3 pts | ||
| Year to date | -99.6% | +11.5% | −111.1 pts | ||
| 1 year | -99.7% | +13.5% | −113.2 pts | ||
| 3 years | -99.9% | +77.7% | −177.6 pts | -89.3% | +21.1% |
| 5 years | -99.9% | +72.6% | −172.5 pts | -73.3% | +11.5% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Silexion Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Results
- News
- News
About Silexion Therapeutics
Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on oncology, specifically developing proprietary therapies for cancers driven by Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations. The company's technology silences oncogenes using chemically modified small interfering RNA (siRNA) constructs that prompt cancer cells to degrade messenger RNA. Its lead product candidate, SIL204, is a second-generation siRNA designed to halt the production of mutated KRAS proteins. SIL204 is administered both intratumorally and systemically via subcutaneous injection in combination with standard chemotherapy to treat patients with locally advanced pancreatic cancer.
Company profile, executives and historySilexion Therapeutics stock: common questions
What is Silexion Therapeutics's stock price?
SLXN closed at $1.98 on Nov 13, 2026, down 25.56% on the day. Over the past 52 weeks it traded between $0.14 and $777.06.
What is Silexion Therapeutics's market cap?
Silexion Therapeutics was worth $1.19M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
Does Silexion Therapeutics pay a dividend?
No. Silexion Therapeutics has not paid a cash dividend over the last twelve months.
When does Silexion Therapeutics report earnings next?
Silexion Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has SLXN stock performed over the past year?
Including dividends, SLXN returned -99.7% over the past year, against +13.5% for the S&P 500.
Who are Silexion Therapeutics's competitors?
Companies most similar to Silexion Therapeutics by business, industry and size include CRDF, SLBT, PMCB, CRIS, BDTX.
See a number that looks wrong?